A pharmaceutical company in Suzhou is mass producing radcivir preparation, which has invested 5 million yuan!

[pharmaceutical network industry trends] it is reported that Borui pharmaceutical, a Suzhou pharmaceutical company, has recently successfully developed the synthesis technology and preparation technology of radcivir APIs, and has mass produced radcivir APIs Currently, it is in the process of mass production of radcivir preparations Up to now, the company's cost incurred in the development and production of raw materials and preparations of radcivir is estimated to be about 5 million yuan, and it is estimated that about 10 million yuan will be invested in the subsequent further scale-up production Data show that Reed novel coronavirus, developed by the American Gillie company, is used for the prevention and treatment of Ebola virus infection It has passed phase I and phase II clinical trials abroad Currently, the company is working with domestic institutions to conduct phase III clinical trials of Reed's new coronavirus infection Gilead said that in view of the urgency of the current situation, Gilead science, the owner of ridcivir, is taking various measures to speed up production and increase supply In February 2nd, China-Japan Friendship Hospital novel coronavirus (Remdesivir) was launched in Wuhan epidemic area to launch the clinical trial of the experimental drug Reed, a new drug for the fight against the epidemic According to the previous introduction of China Japan Friendship Hospital, the end time of the clinical research plan is April 27 At present, there are different voices in the industry about whether or not the generic drug of rhetcivir of Borui medicine can be listed Some think that if we haven't got the authorization from Geely De, the original research enterprise, we can't go public Some also think that China is about to enter the era of high imitation, if ridcivir generic drugs are listed on the market, it will be conducive to reducing drug prices Some experts said that under the current situation of the epidemic, according to the relevant principles of WTO, Borui medicine can be forced to imitate without such constraints Although the third phase of the original research drug has not been completed, if it is required for epidemic prevention and control, the state can approve its listing according to the conditions In November 2001, at the Fourth Ministerial Conference of WTO, one of the historic decisions was to issue the Declaration on the TRIPS Agreement and public health The declaration makes it clear that when developing countries face a serious public health crisis caused by AIDS, tuberculosis, malaria and other infectious diseases, member countries can force the imitation of drugs for these diseases In the view of experts in the industry, under the current situation, compulsory imitation does not violate international practice However, it is understood that after the imitation and preparation production of radcivir API, it still needs to go through many links, such as drug clinical trials, drug approval, etc., which still need to go through a period of test In addition, there are still some uncertain factors in the future, including if the results of the third phase clinical trial of radcivir are not ideal, the imitation technology of radcivir will lose great value; if the epidemic situation is quickly controlled and relieved in a short period of time, and the number of confirmed patients continues to decrease, radcivir may be difficult to be widely used in patients Borui said that it will take the imitation research and development of radcivir as its own social responsibility If the product can be approved for marketing, it will be mainly supplied to relevant patients through donation during the epidemic According to the public information, Borui pharmaceutical landed on the science and technology innovation board on November 8, 2019 Since its establishment, it has been engaged in the R & D and production business of pharmaceutical intermediates, APIs and pharmaceutical products with high technical barriers The customers of products and services are mainly world-famous generic pharmaceutical manufacturers.